AI-Powered Multi-Center Registry for Adult Moyamoya Disease Launches Shandong Sub-Center

On June 1, 2019, the Shandong Sub-center of the Chinese Adult Moyamoya Disease Multicenter Registry Study (CAMD Registry) was established in Jinan. More than 30 hospitals from the Shandong region attended the conference and participated in the plaque-awarding ceremony. Following the launch ceremony in Beijing, sub-centers were separately established in Henan and Shandong, with more than 60 hospitals officially joining the platform.

According to Professor Gu Yuxiang of the Department of Neurosurgery at Huashan Hospital, Fudan University, the “Multicenter Registry Study of Moyamoya Disease in Chinese Adults” leverages ZhongAn Technology’s “Multicenter Medical Imaging Cloud Platform” to conduct nationwide basic and clinical research on moyamoya disease, thereby facilitating big data analytics, clinical trials, and the translation of research findings into practical applications.

As a technology-driven company powered by innovative technologies, ZhongAn Technology has provided comprehensive and multi-dimensional technical support for the platform’s development through technological research and application, thereby facilitating the research and advancement of adult moyamoya disease in China.

“China Adult Moyamoya Disease Multicenter Registry Study” – Presentation Site at the Shandong Sub-Center

Moyamoya disease is a rare chronic cerebrovascular disorder named for the characteristic “puff of smoke” appearance seen on cerebral angiography. This condition poses significant health risks, as patients are at constant risk of sudden ischemic stroke or intracranial hemorrhage, which can lead to limb paralysis, aphasia, coma, or even death. Therefore, under the framework of the National Health Commission’s Stroke Prevention and Control Committee, the “Chinese Adult Moyamoya Disease Multicenter Registry Study,” pioneered by the Department of Neurosurgery at Huashan Hospital Affiliated to Fudan University, holds substantial clinical and public health significance.

Currently, there are numerous challenges in the clinical application of medical imaging, such as non-recognition of diagnostic results across institutions, repeated imaging during patient transfers and referrals, low efficiency and accuracy in image diagnosis, lack of historical imaging data, difficulties in data sharing, and underutilization of imaging data. However, with the increasing maturity of cloud computing applications in the healthcare industry, developing medical imaging cloud services to achieve secure network sharing of imaging data and expand medical imaging applications has become an inevitable trend. The application of cloud computing in healthcare will usher in the era of Data Technology (DT) for the medical industry.

Leveraging cloud computing and artificial intelligence technologies, ZhongAn Technology enables the secure sharing of medical data across healthcare institutions and regions in the cloud. It facilitates rapid data access, data sharing, and the expansion of medical data applications within authorized parameters. This provides more convenient clinical imaging data services for nationwide moyamoya disease research, contributes to the establishment of national electronic health records, promotes regional triage, and supports the advancement of medical research capabilities.

Leveraging a multi-center medical imaging cloud platform, ZhongAn Technology has collaborated with the Department of Neurosurgery at Huashan Hospital, Fudan University, to develop an AI-powered intelligent clinical decision support system for “Moyamoya Disease Diagnosis and Stroke Risk Prediction.” The system has completed the development of its second-stage hemorrhage prediction model, achieving a diagnostic accuracy of 96% for Moyamoya disease and a hemorrhage prediction accuracy of 84%.

To accelerate the resolution of the global challenge in predicting intracerebral hemorrhage in moyamoya disease, ZhongAn Technology began building the “Multi-Center Medical Imaging Cloud Platform” in April 2018. Through nine versions of updates and iterations, the platform’s functionality, ease of use, and security have been continuously optimized and improved. In his presentation at the 2019 National Stroke Conference, Professor Gu Yuxiang highlighted the following features of this platform:

1. Leveraging multimodal data from neuroscience and cerebrovascular diseases, we utilize artificial intelligence, cloud computing, and big data technologies for data analysis, effectively enhancing physicians’ user experience and research capabilities.

2. To address issues such as the large volume of imaging data and prolonged transmission times, the system supports upload lists and resume-from-breakpoint functionality. Additionally, it optimizes medical record information features to minimize manual entry by physicians, thereby reducing input errors and improving data entry efficiency.

3. Desensitize medical data and encrypt it during transmission and storage. Implement independent encrypted storage at the regional, sub-project, and project levels to ensure data security from both technical and operational perspectives.

In the future, the “Multicenter Registry Study of Moyamoya Disease in Chinese Adults” will establish sub-study centers across various regions of China, thereby enabling a multicenter collaborative research network that radiates nationwide from key hubs. ZhongAn Technology will continue to provide technical support for scientific research projects, jointly advancing the development of AI in healthcare and clearing the “fog” surrounding Moyamoya disease.